Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 13/20 | 0.62 |
| ▸ | STK17B | O94768 | 4/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | BCL6 | P41182 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301785 | 0.88 | AURKA (0.57) | STK17ASTK17BAURKABCL6SYK | |
| SCHEMBL301484 | 0.85 | EGFR (0.57) | STK17AAURKAAXLSYK | |
| SCHEMBL10260237 | 0.85 | BCL6 (0.55) | STK17ASTK17BAURKABRD4BCL6 | |
| SCHEMBL303236 | 0.85 | STK17A (0.62) | STK17ASTK17BAURKABRD4BCL6 | |
| SCHEMBL12321383 | 0.84 | SYK (0.55) | STK17ABCL6MEN1KMT2APOLB | |
| SCHEMBL10261544 | 0.83 | SYK (0.47) | STK17ASTK17BAURKABRD4BCL6 | |
| SCHEMBL301485 | 0.82 | AURKA (0.51) | STK17ASTK17BAURKABCL6 | |
| SCHEMBL303841 | 0.82 | BCL6 (0.60) | STK17ASTK17BAURKABRD4BCL6 | |
| SCHEMBL303133 | 0.81 | SYK (0.49) | STK17AAURKABCL6SYK | |
| SCHEMBL270633 | 0.80 | STK17A (0.55) | STK17ASTK17BAURKABRD4AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010017122-A2 | METHODS OF TREATING THALASSEMIA | TARGEGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | STK17A 243/4885STK17B 301/4885AURKA 75/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | STK17A 243/4885STK17B 301/4885AURKA 75/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | STK17A 243/4885STK17B 301/4885AURKA 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.